A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
Completed · Phase 2 · NCT06864143
Conditions: Influenza, SARS-CoV-2
At a glance
- Research payments reported, 2025
- $7.2M
- U.S. investigators named
- 17
- Sites paid
- 24
- Planned or actual enrollment
- 1,320
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1083 Composition 1 Dose A Lot A (biological), mRNA-1083 Composition 1 Dose A Lot B (biological), mRNA-1083 Composition 1 Dose B (biological), mRNA-1083 Composition 1 Dose C (biological), mRNA-1083 Composition 2 Dose A (biological), mRNA-1083 Composition 2 Dose B (biological), mRNA-1083 Composition 3 Dose A (biological), mRNA-1083 Composition 3 Dose B (biological), Influenza Vaccine (biological), COVID-19 Vaccine (biological), Investigational Influenza Vaccine (biological), Investigational COVID-19 Vaccine Lot A (biological), Investigational COVID-19 Vaccine Lot B (biological)
- Dates
- Started 2025-03-07; completion 2025-10-13
- Results posted
- Not yet
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
From ClinicalTrials.gov, last updated 2025-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $7.2M in research payments for this study in 2025 (243 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Daniel Johnson, D.O. Family Medicine · San Diego, CA
- Jon P. Finley, M.D. Sports Medicine · Stockbridge, GA
- Mark A. Turner, MD Family Medicine · Meridian, ID
- Mary Brown, MD Internal Medicine · Rockford, IL
- Matthew D. Wenker, MD Internal Medicine · Erlanger, KY
- Jibran E. Atwi, MD Allergy & Immunology · Lafayette, LA
- James Katz, M.D. Occupational Medicine · Boston, MA
- Shishir K. Khetan, MD Internal Medicine · Rockville, MD
- Brandon J. Lawrence, MD Emergency Medicine · Kalamazoo, MI
- Rebecca A. Rivard, D.O. Family Medicine · Roseville, MI
- Barton G. Williams, MD Family Medicine · Wilmington, NC
- Charles Harper JR., MD Internal Medicine · Norfolk, NE
- Charles H. Eger, M.D Internal Medicine · Cincinnati, OH
- David S. Wheeler, MD Pulmonology · Philadelphia, PA
- Donald Eagerton, M.D. Endocrinology & Diabetes · Myrtle Beach, SC
- Bonnie E. Colville, D.O. Family Medicine · Houston, TX
- Vicki E. Miller, M.D. Family Medicine · Pasadena, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $2.7M
- Texas Center for Drug Development Inc $661,881
- Dynamed Chicago LLC $588,899
- Dynamed Philadelphia LLC $556,703
- Dm Boston LLC $540,019
- Dynamed Clinical Research LP $502,521
- Dynamed Detroit LLC $418,210
- Tma Headlands LLC $342,117
- Headlands Horizons LLC $317,357
- Artemis Headlands LLC $263,799
- Cra Headlands LLC $245,314
- Dm Clinical Research - Bellaire $682
- Velocity Clinical Research-Springdale $458
- Velocity Clinical Research-Rockville $437
- Trial Management Associates, LLC $395
- Velocity Clinical Research - Mt. Auburn $374
- Velocity Clinical Research - Boise $250
- Dm Clinical Research - Philadelphia $208
- Trial Management Associates LLC $187
- Elligo Health Research Inc $187
- Headlands Research - Scottsdale $166
- Headlands Research $166
- Velocity Clinical Research-Norfolk $146
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.